Related references
Note: Only part of the references are listed.Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer
Ina Valeria Zurlo et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)
Combined systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: a prospective study
Ping'an Ding et al.
BMC GASTROENTEROLOGY (2022)
Quality Over Volume: Modeling Centralization of Gastric Cancer Resections in Italy
Laura Lorenzon et al.
JOURNAL OF GASTRIC CANCER (2022)
Evaluation and Comparison of Predictive Value of Tumor Regression Grades According to Mandard and Becker in Locally Advanced Gastric Adenocarcinoma
Yilin Tong et al.
CANCER RESEARCH AND TREATMENT (2021)
Pathologic Complete Response Following Neoadjuvant Therapy for Gastric Adenocarcinoma: A National Cancer Database Analysis on Incidence, Predictors, and Outcomes
Christof Kaltenmeier et al.
AMERICAN SURGEON (2021)
Prognostic value of tumor regression grade following the administration of neoadjuvant chemotherapy as treatment for gastric/gastroesophageal adenocarcinoma: A meta-analysis of 14 published studies
Masato Hayashi et al.
EJSO (2021)
Prognostic value of pathological tumor regression grade in locally advanced gastric cancer: New perspectives from a single-center experience
Pietro Maria Lombardi et al.
JOURNAL OF SURGICAL ONCOLOGY (2021)
Body Composition Changes in Gastric Cancer Patients during Preoperative FLOT Therapy: Preliminary Results of an Italian Cohort Study
Emanuele Rinninella et al.
NUTRIENTS (2021)
A systematic review of HER2 blockade for the curative treatment of gastroesophageal adenocarcinoma: Successes achieved and opportunities ahead
Charlotte I. Stroes et al.
CANCER TREATMENT REVIEWS (2021)
Prognostic and predictive value of mismatch repair deficiency in gastric and gastroesophageal junction adenocarcinoma patients receiving neoadjuvant or adjuvant chemotherapy
Ziyu Li et al.
JOURNAL OF SURGICAL ONCOLOGY (2021)
TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study
Alessandra Raimondi et al.
CANCERS (2021)
Impact of tumor regression grade on recurrence after preoperative chemoradiation and gastrectomy for gastric cancer
Alexander P. Stark et al.
JOURNAL OF SURGICAL ONCOLOGY (2020)
RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction-a randomized phase III joint study of the AIO, ARO and DGAV
Sylvie Lorenzen et al.
BMC CANCER (2020)
Tumor Regression Grade Predicts Survival in Locally Advanced Gastric Adenocarcinoma Patients with Lymph Node Metastasis
Yilin Tong et al.
GASTROENTEROLOGY RESEARCH AND PRACTICE (2020)
D1-plus vs D2 nodal dissection in gastric cancer: a propensity score matched comparison and review of published literature
Laura Lorenzon et al.
BMC SURGERY (2020)
Microsatellite Status Affects Tumor Response and Survival in Patients Undergoing Neoadjuvant Chemotherapy for Clinical Stage III Gastric Cancer
Zhenghao Cai et al.
FRONTIERS IN ONCOLOGY (2020)
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
Salah-Eddin Al-Batran et al.
LANCET (2019)
Is pathologic tumor regression grade after neo-adjuvant chemotherapy a promising prognostic indicator for patients with locally advanced gastric cancer? A cohort study evaluating tumor regression response
Xing Xu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
The association among HER2, MET and FOXP3 expression and tumor regression grading in gastric adenocarcinoma
Eduardo Henrique Cunha Neves Filho et al.
APMIS (2018)
The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI
Salah-Eddin Al-Batran et al.
BMC CANCER (2017)
Tumor response evaluation after neoadjuvant chemotherapy in locally advanced gastric adenocarcinoma: a prospective, multi-center cohort study
Pietro Achilli et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2017)
Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial
Elizabeth C. Smyth et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Tumor regression grade in gastric cancer: Predictors and impact on outcome
Aaron U. Blackham et al.
JOURNAL OF SURGICAL ONCOLOGY (2016)
NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors
Christoph Schulz et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies
Erik von Elm et al.
INTERNATIONAL JOURNAL OF SURGERY (2014)
Japanese classification of gastric carcinoma: 3rd English edition
GASTRIC CANCER (2011)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer
David Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)